GlaxoSmithKline PLC's $3 billion criminal and civil settlement with the U.S. government this week raises questions about the future of asthma treatment Advairthe company's biggest moneymaker and one of the top-selling drugs in the world. According to the U.S. government, from 2001 through "at...
FULL ARTICLE AT Asian Wall Street Journal